ArticleACS medicinal chemistry letters2013
Regenerative medicinal chemistry: the in situ control of stem cells.
Article in ACS medicinal chemistry letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 14 citations in OpenAlex.
- A small-molecule/cytokine combination enhances hematopoietic stem cell proliferation via inhibition of cell differentiation.Stem cell research & therapy · 2017Article
- The protein tyrosine phosphatase 1B inhibitor MSI-1436 stimulates regeneration of heart and multiple other tissues.NPJ Regenerative medicine · 2017Article
- Photocrosslinked ultrathin anionic polysaccharide supports for accelerated growth of human mesenchymal stem cells.Cell proliferation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, there has been mounting evidence to support the presence of stem and progenitor cells within many adult tissues that retain the capacity to proliferate and differentiate, thereby contributing to tissue homeostasis and repair. In line with these discoveries, there have been increasing efforts to develop new agents that target these resident stem and progenitor cell populations in situ to augment or to stimulate repair and regeneration processes. Two such agents are approved drugs, and several more are currently in clinical and preclinical development. Through this emerging therapeutic paradigm there is enormous scope for medicinal chemistry to play a pivotal role in regenerative medicine. The potential impact of regenerative medicinal chemistry is profound, and future studies will reveal which tissue types or disease states will prove most readily tractable through this approach.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.